Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial.
Menarini Ricerche today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611,
Menarini Ricerche, the R&D division of the Menarini Group, announced today that it has treated the first patient in Europe for the cohort expansion part of DIAMOND-01 clinical trial
The spotlight is on the  XXIV   International Fair Play Menarini Award , which was officially presented in Rome. The 2020 programme and winners were revealed in the presence of  CONI (The Italian National Olympic Commit...
The Menarini Group and Radius Health, Inc. (Nasdaq: RDUS) announced today that the companies have entered into an exclusive global license agreement for development and commercialization of elacestrant. Elacestrant is an ora...
Page 1 of 5First   Previous   [1]  2  3  4  5  Next   Last